R1 Inhibitors
Chemicals that function as R1 inhibitors encompass a wide array of compounds that indirectly influence R1 through their action on various cellular and biochemical pathways. These inhibitors are diverse in their targets but share a commonality in their ability to modulate cellular signaling networks, ultimately leading to changes in R1's activity or expression. The majority of these compounds are kinase inhibitors, targeting key enzymes in signaling pathways such as PI3K, MEK, mTOR, JNK, and p38 MAP kinase. These kinases play pivotal roles in regulating cell growth, survival, differentiation, and stress responses. Inhibitors like LY294002, Wortmannin, U0126, PD98059, SP600125, SB203580, Dasatinib, Gefitinib, Imatinib, and Sorafenib disrupt these signaling cascades, leading to a cascade of downstream effects that can indirectly modulate R1. For instance, the inhibition of PI3K/Akt and MAPK/ERK pathways by LY294002 and U0126 respectively, results in altered cell survival and growth signals, which can indirectly influence R1's role in these processes.
In addition to kinase inhibitors, compounds like Rapamycin and SB431542 target other aspects of signaling pathways. Rapamycin, an mTOR inhibitor, impacts cellular growth and proliferation mechanisms, while SB431542, which inhibits TGF-β signaling, influences cellular differentiation and apoptosis pathways. These disruptions can lead to an indirect modulation of R1 as the cell adapts to the altered signaling environment. Overall, R1 inhibitors are characterized by their ability to interfere with signaling networks essential for various cellular functions. By targeting key nodes within these networks, these inhibitors induce a ripple effect, leading to the modulation of R1's activity or expression as part of the cell's adaptive response to the altered signaling landscape.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a potent inhibitor of phosphoinositide 3-kinases (PI3K). By inhibiting PI3K, LY294002 disrupts the PI3K/Akt signaling pathway, which is crucial for many cellular processes including cell survival, growth, and differentiation. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin is an mTOR inhibitor. It binds to FKBP12 and the resulting complex inhibits the mTORC1 pathway. mTOR is a critical component in cell growth, proliferation, and survival. | ||||||
SB 431542 | 301836-41-9 | sc-204265 sc-204265A sc-204265B | 1 mg 10 mg 25 mg | $80.00 $212.00 $408.00 | 48 | |
SB431542 is an inhibitor of the TGF-β type I receptor ALK5, ALK4, and ALK7. It specifically inhibits the phosphorylation of Smad2/3 and blocks TGF-β signaling. Since TGF-β signaling plays a significant role in cellular processes like proliferation, apoptosis, and differentiation, the inhibition of this pathway can indirectly affect R1's function or expression as part of the cellular response to altered TGF-β signaling. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 is a MEK inhibitor that specifically blocks the activation of MEK1, a component of the MAPK/ERK pathway. By preventing MEK1 activation, PD98059 impairs the MAPK/ERK signaling involved in cell growth and differentiation. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is a potent inhibitor of PI3K. Inhibition of PI3K by Wortmannin disrupts the PI3K/Akt signaling pathway, crucial for various cellular processes, including survival and growth. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of c-Jun N-terminal kinase (JNK). By inhibiting JNK, SP600125 disrupts the JNK signaling pathway involved in controlling various cellular processes, including cell proliferation and apoptosis. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is a selective inhibitor of p38 MAP kinase. By inhibiting p38 MAP kinase, SB203580 disrupts the p38 MAPK signaling pathway, which plays a role in stress responses and inflammatory reactions in cells. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $47.00 $145.00 | 51 | |
Dasatinib is a tyrosine kinase inhibitor, primarily targeting BCR-ABL, Src family, c-Kit, and ephrin receptor kinases. By inhibiting these kinases, Dasatinib can influence various signaling pathways involved in cell growth, proliferation, and survival. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $62.00 $112.00 $214.00 $342.00 | 74 | |
Gefitinib is an inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase. By inhibiting EGFR, Gefitinib disrupts the EGFR signaling pathway, which is crucial in regulating cell growth, survival, and differentiation. | ||||||
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $25.00 $117.00 $209.00 | 27 | |
Imatinib is a tyrosine kinase inhibitor that primarily targets BCR-ABL, c-Kit, and PDGFR. By inhibiting these kinases, Imatinib can alter various signaling pathways involved in cell proliferation and survival. | ||||||